MiroBio launches with £27m Series A from leading life sciences investors

新型治疗公司MiroBio融资2700万英镑加强免疫细胞调节研究

2019-10-10 09:33:50 BioSpace

本文共1532个字,阅读需4分钟

Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation Oxford, UK, October 7 2019 –  MiroBio, a novel therapeutics company based on insights into the regulation of receptor signalling in immune cells, has raised £27m ($34m) from a syndicate of international specialist life sciences investors.  Oxford Sciences Innovation and Samsara Biocapital co-led the round and have been joined by Advent Life Sciences and SR One. Proceeds from the Series A fundraising will allow the company to advance its lead programmes, strengthen its proprietary platform, expand its discovery efforts, and build out its management team for the next phase of growth. In conjunction with the financing, Srini Akkaraju MD/PhD, Managing General Partner of Samsara Biocapital, Deborah Harland PhD, Partner of SROne, Andrew Mclean MD, Principal of OSI and Shahzad Malik MD, General Partner of Advent Life Sciences, will join the Board of Directors. MiroBio’s unique platform has its foundations in research and technology from the laboratories of Simon Davis, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford. The company is developing proprietary antibodies and variants to stimulate specific immune cell signals, allowing MiroBio to harness the natural control mechanisms of the immune system for therapeutic benefit across a range of diseases. Initially, MiroBio will focus on applications in auto-immune disease, and is exploring other applications opportunistically. Dr Srini Akkaraju, Samsara Biocapital, said, “MiroBio has an innovative approach to regulating immune cell activity.  By combining this understanding of receptor signalling with detailed knowledge of disease biology and expertise in drug development, we are building a compelling company which has the potential to create meaningful new medicines in a variety of therapeutic indications.” “MiroBio has a robust technology and the ambition to bring new medicines to patients in need of improved therapies,” said Dr Eliot Charles, Executive Chairman of MiroBio and Venture Partner at SROne.  “To help realize this goal, we have assembled a strong syndicate of leading healthcare investors who have a solid track record of creating successful biotech companies and backing world leading teams like the one we have started to build.” Professor Simon Davis, University of Oxford, said, “We have been studying key aspects of signalling through immune cell receptors for over 15 years.  Working collaboratively with MiroBio and its investors, we now have the opportunity to translate our insights, ideas and technologies into important new medicines that could significantly improve patients’ lives.” For further information please contact: MiroBio Dr Eliot Charles, Executive Chairman                                                 comms@mirobio.com                                   About MiroBio MiroBio was established as a spin-out from the University of Oxford in 2019. It is developing antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. Its platform is based on the work of its founding scientists, Simon Davis, Professor of Molecular Immunology, MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford. Their understanding of how immune receptor signalling takes place at the cell surface has generated a platform of IP and technologies which is being exploited by MiroBio.  The company has assembled a team of drug discovery and development experts and is based at the BioEscalator on the University of Oxford’s Old Road clinical campus. It recently raised £27m from an international syndicate of life sciences investors including Advent Life Sciences, Oxford Sciences Innovation, Samsara Biocapital and SR One. For more information please go to www.mirobio.com.
牛津大学的初创公司基于免疫细胞调节方面的深厚专业知识开发了新型疗法 MiroBio ——一家基于对免疫细胞受体信号调节的深入了解的新型治疗公司,已从一家国际专业生命科学投资者财团融资2700万英镑(合3400万美元)。牛津科学创新和 Samsara Biocapital 共同领导了这一轮, Advent Life Sciences 和 SR One 也加入了这一行列。系列 A 融资的收益将使该公司能够推进其主导计划,加强其专有平台,扩大其发现工作,并为下一阶段的增长建立管理团队。在提供资金的同时, Samsara Biocapital 的执行普通合伙人 Srini Akkaraju MD / PhD 、 Deborah Harland 博士、 SROne 的合伙人 Andrew Mclean MD 、 OSI 的负责人 Andrew Mclean MD 和 Advent Life Sciences 的普通合伙人 Shahzad Malik MD 将加入董事会。 MiroBio 独特的平台拥有来自 Simon Davis 实验室、 MRC Weatherall 分子医学研究所分子免疫学教授和牛津大学 Nuffield 临床医学教授 Richard Corall 的研究和技术基础。该公司正在开发专有抗体和变体,以刺激特定免疫细胞信号,使 MiroBio 能够利用免疫系统的自然控制机制,以治疗各种疾病。最初, MiroBio 将专注于自身免疫性疾病的应用,并正在机会主义地探索其他应用。 Samsara Biocapital 的 Srini Akkaraju 博士说,“ MiroBio 有一种创新的方法来调节免疫细胞的活动。通过将对受体信号的理解与疾病生物学的详细知识以及药物开发方面的专业知识结合起来,我们正在建立一家有潜力在各种治疗适应症上创造有意义的新药的公司。” “ MiroBio 拥有强大的技术和雄心,能够为需要改进疗法的患者带来新的药物,” MiroBio 执行董事长兼 SROne 风险合伙人 Eliot Charles 博士说。“为了帮助实现这一目标,我们组建了一个由领先的医疗保健投资者组成的强大财团,他们在创建成功的生物技术公司和支持世界领先团队方面有着良好的业绩记录,比如我们已经开始建立的团队。” 牛津大学的西蒙·戴维斯教授说:“我们已经研究了通过免疫细胞受体传递信号的关键方面超过15年了。与 MiroBio 及其投资者合作,我们现在有机会将我们的见解、想法和技术转化为能够显著改善患者生活的重要新药。” 详情请联络: MiroBio 执行主席 Eliot Charles 博士 comms @ mirobio.com 关于 MiroBio MiroBio 于2019年从牛津大学( UniversityofOxford )拆分出来。它正在开发免疫细胞受体的抗体调节剂,这种方法有潜力跨越一系列疾病,最初的重点是自动免疫疾病。该平台的基础是其创始科学家西蒙·戴维斯、分子医学 MRC Weatherall 研究所分子免疫学教授和牛津大学 Nuffield 临床医学教授理查德·康沃尔的工作。他们对免疫受体信号如何在细胞表面发生的理解,已经产生了一个 IP 平台和技术正在被 MiroBio 开发。 该公司已组建了一个药物发现和开发专家团队,总部位于牛津大学老路临床校区的 BioEscalator 。该公司最近从 Advent Life Sciences 、 Oxford Sciences Innovation 、 Samsara Biocapital 和 SR One 等国际生命科学投资者财团融资2700万英镑。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文